Savara Announces Uplisting to the Nasdaq Global Se

AUSTIN, TX --(Marketwired - October 19, 2017) - Savara, Inc. ( NASDAQ : SVRA ), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that effective as of market open on October 19, 2017, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "SVRA". Nasdaq indicates that the Nasdaq Global Select Market® has the highest initial listing standards of any of the world's stock markets and is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements, and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.

About Savara Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, a Phase III stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, for PAP; AeroVanc, a Phase III stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for HFpEF in Phase II development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com . (Twitter: @SavaraPharma )